150 euros or 10 euros: BioNTech before a decision

Dear readers,

the new week is no longer dominated by the US election. The waves are smoothing out. This should also reduce the great hype surrounding certain stocks from the alternative energies sector. Now it’s about another segment – but all the more acute: the vaccines against the corona virus. It will be concrete – and very challenging on several points. From Germany I see the BioNTech share. There could be a massive price jump there in the very near future – or a crash.

Vaccine: 15 billion doses of vaccine needed?

Should Investors Sell Right Now? Or is it worth joining BioNTech?

I just read about this this morning from a “study” in which a management consultancy worked out together with an authority that we needed 15 billion vaccine doses worldwide. This is an enormous logistical feat. From my point of view, however, such reports are marketing in their purest form.

First of all: we are still a long way from fighting the spread of the corona virus as such reports suggest. To date, there are Russian and Chinese vaccines that are supposed to work. There is great mistrust among us in the West – I leave it that way because I cannot judge it myself.

In the event that we were only dependent on the vaccines in the West, so far BioNTech and Pfizer remain the great hope. The duo have developed a vaccine that is said to be 90% protective. The information is – probably consciously – imprecise because we do not yet know anything about the age groups and various reactions.

Get a free PDF report on BioNTech: Download here for free

Let’s hide that too, but the calculator is still in the way: BioNTech and Pfizer can apparently produce 50 million vaccines this year and up to 1.4 billion vaccine doses in 2021. That is enough – with two doses per person that are required – for almost a tenth of the world’s population who would be vaccinated within a year.

So we are still a long way from an alleged victory or even liberation. On the other hand, it will be exciting these days.

BioNTech and Pfizer are waiting for the vaccine to be approved in the US – or rather, the relevant process to begin. Donald Trump, however, is already pushing for it and apparently wants to leave this good work after a speech in the “rose garden” of the White House on the Friday evening before the weekend (my personal assessment). Then, however, the FDA would have to start in the USA in the coming days. That will happen.

If it were approved, I claim, the share price would gain eminently. If approval is not granted – for example because of side effects – BioNTech shares will plunge into the abyss. If you wanted to “gamble”, now is the time.

Buy, hold or sell BioNTech?

How will BioNTech develop now? Is your money safe in this stock? The answers to these questions and why you need to act now can be found in the current analysis of BioNTech shares.

BioNTech: Buy or Sell? Read more here …

BioNTech Forum